Pular para o conteúdo principal
Ranking Invest

BBIO - BridgeBio Pharma, Inc.

Segmento: HealthcareBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Análise Ranking Invest

Valor de Mercado
$ 13.89 Bi
IVR
-0.37Índice proprietário de comparação relativa: -0,37.
IVR2
-0.17Leitura proprietária complementar: -17%.
MLL
-0.17Leitura proprietária complementar: -17%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 2.53 Bi

Dívida Líquida

$ 1.97 Bi

L4T

-$ 702.02 Mi

MM4T

-107.27%

Indicadores Básicos

ROE

27.80%

Índices de Previsibilidade

Receita Líquida

G0.81

Lucro

B0.19

Margem

D0.66

Índices de Tendência

Receita Líquida

B8.98

Lucro

E-2.55

Margem

A10.46

Índices de Endividamento

DIV/PAT

-0.78

DIV/L4T

-2.81

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.